What Is Ipamorelin? Growth Hormone Research Explained

Ipamorelin is a synthetic pentapeptide, five amino acids in length, developed in the 1990s as a selective growth hormone secretagogue. Its primary studied function is to stimulate the release of growth hormone from the anterior pituitary gland by activating the ghrelin receptor, also known as the growth hormone secretagogue receptor type 1a (GHS-R1a). It was developed by Novo Nordisk and has been the subject of both preclinical and clinical research, primarily in the context of growth hormone deficiency and post-operative recovery.

Ipamorelin is frequently studied alongside CJC-1295, a growth hormone releasing hormone (GHRH) analog that works through a different receptor. The two compounds activate separate pathways that converge on the same target: stimulating the pituitary somatotrophs to release growth hormone in a pulsatile pattern consistent with natural physiology.

The Ghrelin Receptor Pathway

Ghrelin is a hormone produced primarily in the stomach and is most commonly known for its role in appetite stimulation. It is also a potent stimulator of growth hormone release through its binding to GHS-R1a receptors expressed on pituitary somatotrophs. This appetite-and-growth-hormone connection is part of the body's coordinated response to caloric states: during fasting, ghrelin rises, hunger increases, and growth hormone secretion increases to promote fat mobilization and lean mass preservation.

Ipamorelin mimics the growth hormone-stimulating portion of ghrelin's action at the GHS-R1a receptor without fully replicating ghrelin's appetite-stimulating effects. This selectivity was a deliberate design goal and is considered one of ipamorelin's defining research characteristics. Unlike some earlier growth hormone secretagogues that caused significant increases in cortisol, prolactin, and appetite alongside GH stimulation, ipamorelin's receptor binding profile produces a more targeted GH release with less activity at other hormonal axes.

What the Research Has Studied

Ipamorelin's research history spans several application areas.

Growth hormone deficiency. The earliest clinical work with ipamorelin examined its use in individuals with growth hormone deficiency, a condition characterized by insufficient pituitary GH output. Studies demonstrated that ipamorelin administration produced dose-dependent increases in GH and downstream IGF-1 levels, consistent with stimulation of endogenous pituitary function rather than exogenous GH replacement.

Post-operative recovery. A clinical trial conducted by Novo Nordisk examined ipamorelin in patients following abdominal surgery. The study investigated whether stimulating GH release during the post-operative period, when the body is in a catabolic state, could improve recovery markers. The trial showed measurable effects on body composition outcomes but was not continued into later-stage development by Novo Nordisk, likely for commercial rather than safety reasons.

Body composition research. The downstream effects of sustained GH and IGF-1 elevation on body composition have been studied in aging models and clinical populations. GH promotes lean mass accretion and fat mobilization. Research involving ipamorelin and related compounds has examined whether these body composition effects can be produced through secretagogue-mediated endogenous GH release rather than exogenous GH administration, with the hypothesis that the pulsatile, physiological nature of secretagogue-induced GH release may have a different risk profile than synthetic GH injection.

Bone density. IGF-1, the primary downstream mediator of GH action, plays a significant role in bone metabolism. Some research has examined growth hormone secretagogues in the context of age-related bone density decline, with interest in whether sustained GH stimulation can attenuate that process.

Selectivity Compared to Other Secretagogues

The growth hormone secretagogue class includes several compounds with varying selectivity profiles. GHRP-2 and GHRP-6, two older secretagogues studied before ipamorelin, produced stronger GH stimulation but with more pronounced cortisol and prolactin elevation as side effects. Ipamorelin was specifically developed to maintain GH-stimulating potency while reducing these off-target hormonal effects.

This selectivity matters in research contexts because cortisol elevation is catabolic, meaning it breaks down tissue rather than building it, which works against the body composition goals that growth hormone secretagogue research is often designed to address. A secretagogue that raises GH while also raising cortisol produces a mixed signal that complicates interpretation of outcomes.

Regulatory Status

Ipamorelin does not have FDA approval as a drug. It has been available through compounding pharmacies in the United States when prescribed by a physician, though its compounding status has been subject to regulatory changes. The FDA's periodic review of compoundable peptides has affected ipamorelin's availability at various points, and current regulatory status should be verified with a licensed professional before any clinical consideration.

Ipamorelin is frequently studied in combination with CJC-1295. A detailed breakdown of how those two compounds interact as a research stack is available in the pathway science section of this library.